Short interest in Vertex Pharmaceuticals Inc (NASDAQ:VRTX) decreased during the last reporting period, falling from 4.37M to 3.78M. This put 1.66% of the company's publicly available shares short.

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Vera Therapeutics faces a pivotal moment with Phase 3 data expected soon. Depending on the result, the stock may spike or ...

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, ...

Vertex Pharmaceuticals remains on hold with a $494 price target from Stifel analysts after discussions about its chronic pain ...

Shares of Vertex Pharmaceuticals Inc. VRTX slipped 1.68% to $432.00 Tuesday, on what proved to be an all-around mixed trading ...

Buying $1000 In VRTX: If an investor had bought $1000 of VRTX stock 15 years ago, it would be worth $11,812.35 today based on ...

Received overwhelming shareholder approval with 99.9% of votes cast in favorSimplified structure benefits shareholders through strengthened shareholder alignment, enhanced governance, significant cash ...

Vertex Pharmaceuticals is making waves with its new pain treatment, Journavx, which is experiencing a prescription growth ...

CNW/ - DRI Healthcare Trust (TSX: DHT.UN) (TSX: DHT.U) (the "Trust") today announced its financial results for the quarter ...

The administration doesn't believe there are questions about its legal authority to influence price negotiations pharma ...